Citius Pharmaceuticals Inc (CTXR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.69M
Last updated: Nov 17, 2026 at 11:00 AM ET
Citius Pharmaceuticals Inc (CTXR) Competitors
The companies most similar to Citius Pharmaceuticals are Cyclerion Therapeutics (CYCN), Context Therapeutics (CNTX) and Cocrystal Pharma (COCP). By market cap, Citius Pharmaceuticals ranks 9th of the 13 companies on this page; NextCure (NXTC) is the largest at $29.31M.
Peer Comparison
CTXR's ROIC of -84.3% is above the peer median of -650.8%, and its revenue growth of 0.0% is above the median of -1.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Citius Pharmaceuticals (CTXR) | $14.69M | N/A | 1.9x | 0.0% | -84.3% | 0.0% | 0.00% |
| Cyclerion Therapeutics Inc (CYCN) | $15.73M | N/A | N/A | 0.0% | N/A | -43.2% | 0.00% |
| Context Therapeutics Inc (CNTX) | $16.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cocrystal Pharma Inc (COCP) | $18.88M | N/A | 39.2x | 0.0% | N/A | 26.9% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Biocardia Inc (BCDA) | $12.58M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Intensity Therapeutics, Inc. Common stock (INTS) | $10.17M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Passage Bio Inc (PASG) | $13.68M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tvardi Therapeutics, Inc. (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Lite Strategy, Inc. (LITS) | $25.30M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $9.90M | N/A | 16.4x | 0.0% | -72.3% | -15.9% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Peer median | $15.73M | N/A | 12.6x | 0.0% | -650.8% | -1.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Citius Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Cyclerion Therapeutics Inc (CYCN) | Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development... | |
| Context Therapeutics Inc (CNTX) | Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid... | CNTX competitors |
| Cocrystal Pharma Inc (COCP) | Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic... | COCP competitors |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Biocardia Inc (BCDA) | BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. | BCDA competitors |
| Intensity Therapeutics, Inc. Common stock (INTS) | Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. | INTS competitors |
| Passage Bio Inc (PASG) | Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. | PASG competitors |
| Tvardi Therapeutics, Inc. (TVRD) | Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet... | TVRD competitors |
| Lite Strategy, Inc. (LITS) | Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. | LITS competitors |
| NextCure Inc (NXTC) | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human... | |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
Frequently Asked Questions About CTXR
Who are Citius Pharmaceuticals' main competitors?
The companies most similar to Citius Pharmaceuticals include Cyclerion Therapeutics (CYCN), Context Therapeutics (CNTX), Cocrystal Pharma (COCP), Plus Therapeutics (PSTV) and Biocardia (BCDA), listed from the closest match.
Who is Citius Pharmaceuticals' biggest competitor?
NextCure (NXTC) is the largest of the similar companies at $29.31M; Cyclerion Therapeutics (CYCN) is the closest match by business profile, size, sector and industry.
How does CTXR stock compare with its competitors?
CTXR's P/S is 1.9x against a peer median of 12.6x; its net margin is 0.0% against a peer median of 0.0%.
Which of Citius Pharmaceuticals' competitors pays a higher dividend?
Citius Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Citius Pharmaceuticals bigger than its competitors?
No. Citius Pharmaceuticals is 9th by market cap among the 13 companies on this page; the largest is NextCure (NXTC) at $29.31M.
CTXR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors